Regeneron Pharmaceuticals, Inc. (REGN) 은(는) 상장 기업입니다 헬스케어 섹터의 바이오 산업에서 운영. 본사 소재지는 Tarrytown, NY, 미국. 현재 CEO는 Leonard S. Schleifer.
REGN 을(를) 보유 IPO 날짜 1991-04-02, 15,158 명의 정규직 직원, 에 상장 NASDAQ Global Select, 시가총액 $78.34B.
Regeneron Pharmaceuticals, Inc. is a global biopharmaceutical company that discovers, develops, manufactures, and commercializes innovative medicines for serious diseases. The company's marketed portfolio includes EYLEA for retinal diseases, Dupixent for atopic dermatitis and asthma, Libtayo for cutaneous squamous cell carcinoma, Praluent for cardiovascular disease, Kevzara for rheumatoid arthritis, and several other specialized therapies for infectious, rare, and cancerous conditions. Regeneron maintains extensive collaboration agreements with leading pharmaceutical and biotechnology companies including Sanofi, Bayer, Roche, and AstraZeneca, as well as strategic partnerships with research institutions and government health agencies. Founded in 1988 and headquartered in Tarrytown, New York, the company focuses on high-value therapeutic areas including ophthalmology, immunology, cardiovascular disease, and oncology.
